gbola amusa md cfa head hc research
sale trade et
share mil
creat bluematrix
cbio buy good one
cautiou binari biotech risk
incom mm significantli beat ccme mm due
mm unmodel licens collabor revenu report
ep beat ccme ep beat con ep
 report mm vs ccme mm sg mm vs
mm expens line ccme compani end
mm cash equival mm end
driven mm gross proce februari
common stock offer noteworthi item quarter us includ
april catalyst announc pivot phase
trial design subq engin factor viia fviia marzeptacog
alfa activ marzaa individu hemophilia
inhibitor design incorpor guidanc fda
ema catalyst plan enrol first patient end year
april catalyst announc complet phase iib
trial subq engin factor ix dalcinonacog alfa hemophilia
 final phase iib dalca result present
data eahad februari suggest catalyst gt construct
cb may significantli reduc vector dose requir
gene therapi treatment maintain high factor activ level
model updat beat driven book up-front
payment unrat beyond estim
modestli affect rate pt thu unchang
thesi updat continu see upwardli skew risk/reward
dynam cbio potenti upsid
catalyst dose marzaa pivot phase trial end
thu attract investor later-stag biotech asset
along way catalyst strike clearly-posit marzaa deal big
biopharma thu return investor confid catalyst dataset
catalyst strike clearly-posit deal big biopharma cb
gt note big biopharma hemophilia player avail
hyperact transgen -padua cb ip
protect buy-rat uniqur catalyst respect
catalyst gener final dalca phase iib data piqu
investor interest view least like sourc upsid
marzaa report final data marzaa phase pk/pd studi
dalca present final phase ii trial data hemophilia
pleas refer import disclosur inform regul analyst certif found page report
cb report initi non-human primat data hemophilia
marzaa dose patient pivot phase trial hemophilia inhibitor
februari cbio buy pt housekeep updat result offer
decemb dri collabor show cbio scienc real
novemb cbio buy may show piii hemophilia play stay cash
august cbio buy marzaa catalyst may becom phase compani
februari cbio buy synthet transgen activ -padua
januari cbio buy catalyst enter gene therapi space
decemb cbio buy buy weak dalca nab issu gain visibl
decemb cbio buy day dose nab isr marzaa
septemb cbio buy investor dinnerth market ascrib pii/iii marzaa
june cbio buy cb marzaa manufactur differ posit
june discount cash marzaa data upcom
march cbio buy posit ahead marzaa
februari cbio buy pt phase i/ii cb data hemophilia
june reiter buy cb phase i/ii support valuat potenti hemophilia
rate catalyst bioscienc cbio buy potenti subq-administ therapeut marzaa dalca
meet unmet need conveni complianc safeti efficaci patient bleed disord catalyst
lead asset engin activ factor vii fviia marzaa marzeptacog alfa hemophilia inhibitor
engin factor ix dalcinonacog alfa dalca hemophilia product offer potenti simpl
subq self-administr higher stabl factor level thu avoid safeti efficaci issu
associ peak trough tradit factor use offer follow reason cbio
catalyst trade rel close cash despit two asset marzaa dalca phase ii develop
marzaa hemophilia inhibitor catalyst shown posit interim phase ii result name
reduct bleed abr pdb product safe well toler
anti-drug antibodi subq inject total thu believ product catalyst argu
potent novoseven rt credibl chanc hem inhibitor market expect share price
momentum catalyst execut guid transit marzaa phase trial
dalca hemophilia dalca associ steep cbio price declin around june immunogen
question catalyst sinc work improv manufactur sinc deem dalca inher
immunogen show similar immunogen profil benefix novemb releas
individu complet day dose compani report ada inhibitor detect await
announc final phase iib data believ upsid possibl either issu dalca
immunogen inde resolv issu read-across marzaa
cb hemophilia catalyst preclin aav-bas gene therapi gt use dalca transgen
construct view potent tradit therapeut may mean fraction product may
deliv achiev similar activ level compet product believ cb assum limit
issu immunogen may valuabl option catalyst prove attract bigger cap player
yet credibl strategi hemophilia gt especi fix-padua head toward standard-of-car statu
cb dri announc global licens collabor agreement unrat biogen
cb us support scienc catalyst asset marzaa dalca cb like cb
seek address dose limit current standard care collabor catalyst
receiv million up-front million mileston tier royalti low doubl digit
page
catalyst bioscienc cbio price target base probability-adjust model key franchis
use dcf wacc perpetu growth impli termin ebitda multipl
note conserv use share count mm denomin dcf per-shar valuat includ
addit dilut futur mm offer may share price without benefit
mm cash increas valuat conserv approach model lead cbio price target
risk achiev target price
clinic risk clinic studi marzaa hemophilia inhibitor might fail show efficaci
subcutan subq prophylact therapi might gener safeti issu exampl thromboembol event might
lead format anti-drug antibodi creat efficaci and/or safeti risk moreov trial dalca
hemophilia might fail show efficaci subq therapi due nab might gener safeti issu
regulatori risk certainti catalyst drug approv reimburs us elsewher
regulatori pathway prove complex and/or time consum anticip could materially-
neg impact project target price even assum result catalyst franchis achiev
target endpoint product obtain regulatori approv risk-adjust project price target
would expos downward revis
commerci risk potenti catalyst indic may larg project highlight
competit hemophilia inhibitor alnylam buy novo nordisk unrat roch unrat
takeda unrat highlight competit hemophilia alnylam buy behr privat freelin
therapeut unrat takeda unrat uniqur buy chardan top pick addit catalyst
build sale market medic affair infrastructur us possibl global region
financ risk catalyst potenti need rais addit capit fund clinic trial perhap via equiti
financ reach profit potenti result share dilut sharehold
stock price volatil share price volatil common development compani biotechnolog sector
catalyst bioscienc found went public august merger targacept catalyst
develop product bleed disord compani lead asset engin activ factor vii marzaa
treatment hemophilia inhibitor complet phase ii trial second asset engin factor ix
dalca treatment hemophilia complet phase iib trial catalyst preclin pipelin includ aav-
base gene therapi cb hemophilia system complement inhibitor dri age-rel macular
degener catalyst headquart south san francisco california
page
rate price target histori catalyst bioscienc inc cbio
creat bluematrix
rate price target histori uniqur qure
creat bluematrix
rate price target histori inc
distribut ratings/ib servic
creat bluematrix
page
analyst certif analyst respons cover secur report certifi view
express research report accur reflect person view compani secur analyst
respons cover secur report certifi part compens directli
indirectli relat specif recommend view contain research report
